What is the recommended surveillance schedule for a patient with grade‑one goblet‑cell adenocarcinoma confined to the appendix after a complete right hemicolectomy with negative margins?

Surveillance for Grade 1 Goblet Cell Adenocarcinoma Confined to Appendix

For a patient with grade 1 goblet cell adenocarcinoma confined to the appendix after complete right hemicolectomy with negative margins, implement a modified colorectal cancer surveillance protocol with history, physical examination, and CEA testing every 3-6 months for 5 years, annual CT imaging (chest and abdomen) for 3 years, and colonoscopy at 1 year then every 5 years.

Rationale and Evidence-Based Approach

The available guidelines do not specifically address goblet cell adenocarcinoma surveillance, as this is a rare appendiceal malignancy. However, the ASCO colorectal cancer surveillance guidelines 1 provide the most applicable framework, as goblet cell adenocarcinoma shares features with both neuroendocrine and adenocarcinoma histologies and is managed similarly to colorectal cancer after complete resection.

Clinical Visits and Laboratory Monitoring

• History, physical examination, and CEA testing every 3-6 months for 5 years 1
  • For grade 1 (low-grade) disease confined to the appendix with negative margins, the lower-risk end of this range (every 6 months) is reasonable
  • 80% of recurrences in colorectal cancer occur within the first 2-2.5 years, and 95% by 5 years 1
  • Recent data on appendiceal mucinous neoplasms shows recurrence risk is highest in the first 16 months post-surgery 2, supporting more intensive early surveillance

Cross-Sectional Imaging

• Annual CT scan (chest and abdomen) for 3 years 1
  • This is appropriate for low-grade, completely resected disease
  • PET scans should not be used for routine surveillance 1
  • The ESMO guidelines for colon cancer recommend liver ultrasound every 6 months for 3 years, then at years 4 and 5 3, but CT provides more comprehensive assessment

Endoscopic Surveillance

• Colonoscopy at 1 year after surgery, then every 5 years if normal 1
  • If complete colonoscopy was not performed before diagnosis, perform after completion of any adjuvant therapy (before the 1-year mark) 1
  • Adjust frequency based on findings of previous colonoscopy 1

Important Caveats and Clinical Considerations

Grade 1 disease has better prognosis: The recent literature confirms that goblet cell adenocarcinomas have variable outcomes based on grade 4, 5. Your patient's grade 1 (low-grade) histology with complete resection and negative margins places them in a lower-risk category, justifying less intensive surveillance compared to higher-grade disease.

Recurrence patterns: While appendiceal goblet cell carcinomas can recur 4, completely resected low-grade disease has significantly better outcomes. The 5-year overall survival for goblet cell carcinomas is approximately 85% 4, though this includes all grades and stages.

Surveillance should be risk-stratified: The ASCO guidelines emphasize that surveillance intensity should match recurrence risk and the patient's functional status 1. If early detection would not lead to aggressive treatment (due to comorbidities), surveillance testing should not be performed 1.

Symptom monitoring: Any new, persistent, or worsening symptoms warrant immediate evaluation for recurrence 1, regardless of the scheduled surveillance timeline.

Practical Implementation

Years 1-2 (highest risk period):

• Office visits with history, physical exam, and CEA: every 6 months
• CT chest/abdomen: annually
• Colonoscopy: at 1 year

Years 3-5:

• Office visits with history, physical exam, and CEA: every 6 months
• CT chest/abdomen: at year 3 only
• Colonoscopy: at year 5 (if 1-year colonoscopy was normal)

After 5 years:

• Return to routine colonoscopy screening every 5 years
• No routine imaging or CEA testing unless symptomatic

This approach balances the need for early detection of recurrence (when curative intervention is possible) against the low absolute risk of recurrence in completely resected, low-grade disease.